Under new regulations, Centers for Medicare and Medicaid Services (CMS) will begin to limit its role in making sure exchange plans comply with certain Affordable Care Act (ACA) requirements – including reviews for prescription drug benefits – beginning in 2018. The changes came in a final rule last week, and could mean that in states where CMS is not conducting reviews, more expensive medications could be placed on higher drug tiers with larger out-of-pocket costs for patients. Several chronic disease groups have sought to limit that practice in the past. Read more here.
Last Updated on May 13, 2020 by Aimed Alliance
